We would love to hear your thoughts about our site and services, please take our survey here.
BTW - I am all in on SNG and still hope sun will shine on us one day
Could you advise a stockbroker who you think are good at UK n USA markets please?
I am not a trader but been with HSBC for my LTH transactions but feel they are rubbish.
If you could recommend a broker for someone who does minimum transactions that would be appreciated!
Also any transfer options of ISA from HSBC to new broker would be appreciated. Thanks in advance.
“ Scientists say don't treat Omicron like a cold just yet — it could cause more havoc than Delta, even if symptoms appear 'mild'”
https://ca.news.yahoo.com/scientists-were-not-yet-ready-151857526.html
Polar
Thanks Helen.
Looked at below date in 2021 and misread.
“Date Agreed to Recruit Target Number of Patients = 15/05/2021”
Recruitment finished - 11/05/2021
Sno 76 - At the end of the document
https://mft.nhs.uk/app/uploads/2020/10/NIHR-Delivery-Q2-2020-21.pdf
https://www.proactiveinvestors.co.uk/pdf/create/news/details/950837
Good to see you back pmjh.
No proof of Remdesivir's effectiveness in COVID patients; may be dropped soon.
https://www.indiatvnews.com/news/india/remdesivir-may-be-dropped-soon-as-there-is-no-proof-of-its-effectiveness-in-treating-covid19-patients-705500
“ “With the appearance and rapid circulation of mutations, it is important to have broad spectrum treatments. With the exogenous administration of Interferon beta, the organism's own antiviral mechanisms are activated that could serve to combat SARS-CoV-2, regardless of the variant that is circulating ”, Cao warns.
This exploratory trial consists of studying the technical viability of the pharmaceutical asset, which has proven safety in other treatments.
Currently, the protein produced by Biosidus is the International Standard selected by the European Pharmacopoeia among dozens of high quality biosimilar products.
"In the fight against COVID-19, the association and joint work of Argentine biotechnology companies is key, whose talent, technologies and innovation capacity are of excellence and have allowed Argentine science to be brought to the world for many years," said Mariano de Elizalde, CEO & President of Biosidus.”
End 2/2
https://twitter.com/hub247/status/1385868308285730816?s=21
https://www.clarin.com/tecnologia/cientificos-argentinos-cerca-nuevo-tratamiento-coronavirus_0_7GuZUtZiF.html
Translated:
“With a focus on lung diseases, Argentine technicians and scientists are working on innovative inhalation technologies that allow them to respond to respiratory diseases such as the coronavirus.
With the arrival of SARS-CoV-2 and taking into account that this virus affects the respiratory tract, the Proinvet Innovations team of experts began to develop a technology to nebulize therapeutic proteins and target them specifically to the lung mucosa.
"We have been working for more than 2 years on formulations that were able to stabilize proteins subjected to the molecular stress generated by nebulization, in order to have new therapeutic targets for respiratory diseases", explains Mariano Cao, general director of ProinVet Innovations.
The strategy consists of using Biosidus Interferon beta 1a, a protein that humans naturally activate in response to viral infections and that triggers a protective response against these pathogens.
In the midst of this investigation, the Covid-19 epidemic was unleashed, which is still active. And in early 2020, in the earliest stage of the pandemic, the team decided to focus on a method to contain this family of viruses that can cause disease in animals and humans.
“We set about adapting our knowledge to try to nebulize interferon efficiently, while maintaining its bioactivity. Luckily we were successful and we managed to have a very robust treatment in the laboratory ”, Cao reports.
This treatment, still in the exploratory trial phase, is being tested successfully at the Hospital de Clínicas in patients with coronavirus and the Faculty of Medicine of the University of Buenos Aires. If successful, it could be prescribed by clinicians.
We put all the energy into testing it on patients to see how effective it is. With the trial that is ongoing, we hope to be able to see the viability of the technology and then carry out an expanded study that allows the treatment to be registered, ”says Cao.
Numerous clinical evidence obtained in various countries indicates that interferon beta 1a nebulization is safe.
“Getting this development started is what we look forward to most to be able to contribute in the fight against this virus. Our team of scientists has done an unprecedented and admirable job, where science has been put at the service of humanity ”, warned Daniel Sammartino, president of ProinVet Innovations.
Prevent spread
Treatment could shorten infection times and prevent disease progression to more severe stages in patients infected with SARS-CoV-2. Consequently, the spread of the virus could be decreased.”
Contd.. 1/2
Matterhorn, Not sure if you noticed but the Date is Mar 31st
SNG mentioned, interferons section.
https://covdb.stanford.edu/page/covid-review/#interferons
https://twitter.com/entrepreneur987/status/1385525106722496516?s=21
https://twitter.com/bloombergquint/status/1385524282483040257?s=21
Not sure if this already posted.
Is this ACTIV-2 international arm?
Interferon-ß-1a in the treatment of Covid-19:
“ March 30, 2021. Interferon-ß for the home care of Covid-19 patients over 65: a CNR, ISS, INMI study is underway
# NEW To treat Covid-19 patients over 65 with mild symptoms with Interferon beta at home , is the objective of the experimental study, approved by AIFA and ready to enroll patients in the Roman territory. Read the ISS press release”
http://www.nbst.it/989-coronavirus-nuovi-farmaci-per-cura-covid.html#interferone
https://www.iss.it/news/-/asset_publisher/gJ3hFqMQsykM/content/id/5682934
“ Conclusion
NIAID continues to expand efforts to elucidate the biology, pathogenesis, and clinical manifestations of SARS-CoV-2 infection, including emerging variants, and to employ this knowledge to develop safe and effective interventions to diagnose, treat, and prevent SARS-CoV-2 infection and COVID-19. NIAID is focused on developing safe and effective SARS-CoV-2 vaccines and therapeutics and sensitive, specific, and rapid point-of-care molecular diagnostic and serological tests. NIAID also is conducting early stage research on candidate vaccines that could protect against multiple strains of coronaviruses. These efforts will improve our response to the current pandemic and bolster our preparedness for the next, inevitable viral disease outbreak.”
This to me assures ACTIV 2 is progressing well.
“ ACTIV-2, which is focused on outpatients, has since been expanded to evaluate a combination monoclonal antibody therapy, BRII-196 and BRII-198, as well as three investigational therapeutics: SNG001, an inhalable beta interferon; AZD7442, an investigational long-acting antibody combination; and camostat mesilate, an orally administered molecule that may block SARS-CoV-2 from entering cells.”
https://docs.house.gov/meetings/VC/VC00/20210415/111426/HHRG-117-VC00-Wstate-FauciMDA-20210415.pdf
“ Another drug that caused a bit of controversy is [Synairgen’s] inhaled interferon. This was in the original protocol, but was dropped because the company and the investigators who were developing it decided that RECOVERY wasn't the appropriate vehicle. They started their own phase II trial, which subsequently showed a potential benefit. But it was a small trial. They've moved on to a larger trial.”
https://www.nature.com/articles/d41573-021-00068-w